tetano
Editor, Senior Moderator
Biochem Biophys Rep
. 2020 Dec;24:100844.
doi: 10.1016/j.bbrep.2020.100844. Epub 2020 Nov 5.
SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes
Vikas Kumar Bhari[SUP] 1 [/SUP], Durgesh Kumar[SUP] 2 [/SUP], Surendra Kumar[SUP] 3 [/SUP], Rajeev Mishra[SUP] 1 [/SUP]
Affiliations
Abstract
The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite COVID-19 pandemic got center stage at present time, however very little research being explores, which increase our knowledge in context with how SARS-CoV-2 infection affect cancer a cellular level. Therefore, in light of the ACE-2 as an important contributor of COVID-19 global, we analyzed correlation between ACE2 and tumor immune infiltration (TIL) level and the type markers of immune cells were investigated in breast cancer subtypes by using TIMER database. Our findings shed light on the immunomodulatory role of ACE2 in the luminal A subtype which may play crucial role in imparting therapeutic resistance in this cancer subtype.
Keywords: ACE2; Breast cancer; COVID-19; Genomics; Immunomodulation.
. 2020 Dec;24:100844.
doi: 10.1016/j.bbrep.2020.100844. Epub 2020 Nov 5.
SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes
Vikas Kumar Bhari[SUP] 1 [/SUP], Durgesh Kumar[SUP] 2 [/SUP], Surendra Kumar[SUP] 3 [/SUP], Rajeev Mishra[SUP] 1 [/SUP]
Affiliations
- PMID: 33178900
- PMCID: PMC7643628
- DOI: 10.1016/j.bbrep.2020.100844
Abstract
The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacted the world severely. The binding of the SARS-CoV-2 virus to the angiotensin-converting enzyme 2 (ACE2) and its intake by the host cell is a necessary step for infection. ACE2 has garnered widespread therapeutic possibility as it is entry/interactive point for SARS-CoV-2, responsible for coronavirus disease 2019 (COVID-19) pandemic and providing a critical regulator for immune modulation in various disease. Patients with suffering from cancer always being on the verge of being immune compromised therefore gaining knowledge about how SARS-CoV-2 viruses affecting immune cells in human cancers will provides us new opportunities for preventing or treating virus-associated cancers. Despite COVID-19 pandemic got center stage at present time, however very little research being explores, which increase our knowledge in context with how SARS-CoV-2 infection affect cancer a cellular level. Therefore, in light of the ACE-2 as an important contributor of COVID-19 global, we analyzed correlation between ACE2 and tumor immune infiltration (TIL) level and the type markers of immune cells were investigated in breast cancer subtypes by using TIMER database. Our findings shed light on the immunomodulatory role of ACE2 in the luminal A subtype which may play crucial role in imparting therapeutic resistance in this cancer subtype.
Keywords: ACE2; Breast cancer; COVID-19; Genomics; Immunomodulation.